As of April 20, there are 2,440,528 confirmed coronavirus cases and 167,592 deaths globally. Currently, the U.S. continues as the hardest-hit country in the world, with 749,666 total cases – 238,831 of which are in the current epicenter, New York. In deciding timelines for reopening economies, officials from affected countries, including Italy, Spain, China, and the U.S., are relying on AI/ML-powered predictive models to determine next best actions. Given the unpredictability and rapidly-changing pandemic climate, AI/ML is necessary to overcome COVID-19 eventually.
Pharma companies realize the value of data-driven insights and decision making and employing best-in-class technology and infrastructure to enable them. So, in recent years, pharma companies are investing heavily in big data solutions. However, these systems do not yield the kind of value expected from the investment. Some of the reasons include: